Review anchor
HT-29
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
HT-29
CHEMBL384
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HT-29 as ChEMBL target CHEMBL384. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL384
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why HT-29 matters
HT-29 is reviewed as HT-29; the current evidence base includes 104 approved drugs, 65805 compounds, and 7669 assays, with lead potency reaching pChEMBL 11.0.
Protein context
HT-29
HT-29
Review this target as HT-29.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 104 approved drugs, 65805 compounds, and 7669 assays for this target. The dominant activity type is IC50. CHEMBL265841 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL265841 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
104 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why HT-29 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
65805
Total Compounds
7669
Total Assays
104
Approved Drugs
IC50: 17580.0, EC50: 1560.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL265841
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL90555
|
11.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL284083
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL1806651
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL290566
|
10.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
TIRBANIBULIN
CHEMBL571546
|
2020 |
|
|
PLITIDEPSIN
CHEMBL451930
|
2018 |
|
|
COPANLISIB
CHEMBL3218576
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
PANOBINOSTAT
CHEMBL483254
|
2015 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
BELINOSTAT
CHEMBL408513
|
2014 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
VEMURAFENIB
CHEMBL1229517
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
MYCOPHENOLIC ACID
CHEMBL866
|
2004 |
|
|
IMATINIB
CHEMBL941
|
2001 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
PODOFILOX
CHEMBL61
|
1990 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
NICLOSAMIDE
CHEMBL1448
|
1982 |
|
|
DIGITOXIN
CHEMBL254219
|
1982 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DAUNORUBICIN
CHEMBL178
|
1979 |
|
|
DAUNORUBICIN HYDROCHLORIDE
CHEMBL1563
|
1979 |
|
|
DIGOXIN
CHEMBL1751
|
1975 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
PLICAMYCIN
CHEMBL1237054
|
1970 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
VINBLASTINE SULFATE
CHEMBL378544
|
1965 |
|
|
DACTINOMYCIN
CHEMBL1554
|
1964 |
|
|
VINCRISTINE SULFATE
CHEMBL501867
|
1963 |
|
|
VINCRISTINE
CHEMBL90555
|
1963 |
|
|
FLUOROURACIL
CHEMBL185
|
1962 |
|
|
COLCHICINE
CHEMBL107
|
1961 |
|
|
METHOTREXATE
CHEMBL34259
|
1953 |
|
|
EMETINE
CHEMBL50588
|
— |
Source Header